

Richard T. Jackson, M.D., Inc.  
NEW RIVER VALLEY NEUROLOGY CLINIC

DIPLOMATE, AMERICAN BOARD OF  
PSYCHIATRY & NEUROLOGY,  
(WITH ADDED QUALIFICATIONS IN CLINICAL NEUROPHYSIOLOGY)  
ADULT & CHILD

707 RANDOLPH STREET, SUITE 250  
RADFORD, VIRGINIA 24141-2429  
(540) 731-1454

FAX (540) 731-1072

November 20, 1998 1629

99 MAR 24 12:12

Kimberly Popper  
Center for Drug Evaluation & Research  
(HFD21) FDA  
5600 Fisher's Lane  
Rockville, MD 20857


Dear Mrs. Popper:

I recently became aware that the drug, 4-Aminopyridine, will soon become unavailable. As you know, this medication has been shown to benefit a small but definite number of patients with Multiple Sclerosis. I have at least 5 patients in my practice who have benefited from this medication and who would lose some of their walking skills if it became unavailable. Please add 4-APAP to the list of drugs that will be approved for compounding.

Sincerely,

Richard T. Jackson, M.D.

RTJ/ns



98N-0182

C112